X

Drug Profile

NTB 010

Alternative Names: ABI-010; nab®-17AAG; NTB-010

Latest Information Update: 12 Sep 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Abraxis BioScience
Developer NantBioScience
Class Antineoplastics
Mechanism of Action Heat-shock protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Solid tumours

Most Recent Events

21 Aug 2024 Abraxis BioScience has been acquired and merged into Celgene Corporation prior to October 2010
21 Aug 2024 Abraxis files an IND application with the FDA in USA for Solid tumours
21 Aug 2024 NantBioScience plans a clinical for NTB 010 in 2015

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com